v3.26.1
Segment Information
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

7. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

 

The CODM, who is the Chief Executive Officer (“CEO”), President, and Chairman of the Board, manages and allocates resources to the operations of the Company on an entity-wide basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on an entity-wide basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 

Given the Company’s September 2025 strategic pivot to prioritize the development and distribution of Tome skincare products, the segment information disclosure has been recast for all periods presented to reflect this change. The following table summarizes the segment’s financial information including the Company’s significant segment expenses:

 

   2026   2025 
  

Three Months Ended

March 31,

 
   2026   2025 
Research and development  $      $    
Clinical   -    726,321 
Chemistry, manufacturing and controls and nonclinical   32,502    125,290 
Personnel related   351,222    429,530 
Total research and development  $383,724   $1,281,141 
Selling, general and administrative          
Compliance   1,011,796    719,644 
Marketing   206,333    - 
Personnel related   324,529    339,018 
Total selling, general and administrative   1,542,658    1,058,662 
Interest income   78,676    36,216 
Net loss  $(1,847,706)  $(2,303,587)